Proof of Principle of the best-in-class therapeutic mRNA cancer vaccine

Project description

New vaccine for HPV16-positive cancer tested

The EU-funded TIGER project will demonstrate the benefits of a novel mRNA cancer vaccine platform optimised for intravenous administration into patients. The antigens that will be used to deliver proof of principle comprise mRNAs encoding the proteins E6 and E7 of the human papillomavirus strain 16 (HPV16) and TriMix mRNAs that act as an adjuvant to stimulate dendritic cells to initiate strong T-cell responses. The study will be in patients with recurrent HPV16-positive cancer without and with a PD-1 checkpoint inhibitor. Safety, immunogenicity and clinical benefit will be key endpoints for this study. Once validated, the platform will be readily translatable to a wide range of cancers using other tumour antigens.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drug › vaccines
• medical and health sciences › clinical medicine › cancer

Programme(s)

• H2020-EU.3.1.3. - Treating and managing disease

Topic(s)

• SC1-BHC-08-2020 - New interventions for Non-Communicable Diseases

Call for proposal

H2020-SC1-2020-Two-Stage-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

ETHERNA IMMUNOTHERAPIES

Address

Galileilaan 19
2845 Niel
Belgium

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU contribution

€ 5 094 401,25

Participants (7)

SAGA DIAGNOSTICS AB

Sweden

EU contribution

€ 186 187,50

Address

Scheelevagen 2, Mv-401
223 81 Lund

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

STICHTING VUMC

Netherlands

EU contribution

€ 241 226,25

Address

De Boelelaan 1117
1081 HV Amsterdam

Activity type

Research Organisations

CLINIQUES UNIVERSITAIRES SAINT-LUC

Belgium

EU contribution

€ 311 435

Address

Avenue Hippocrate 10
1200 Bruxelles

Activity type

Research Organisations

EUROPEAN CANCER PATIENT COALITION

Belgium

EU contribution

€ 223 125

Address

Rue Montoyer 40
1000 Bruxelles

Activity type

Other

ONCORADIOMICS

Belgium

EU contribution

€ 400 000

Address

Clos Chanmurly 13
4000 Liege

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

CERATIUM BV

Netherlands

EU contribution

€ 221 812,50

Address

Veemkade 240
1019 HD Amsterdam

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

PATERGRUS BVBA

Belgium

EU contribution

€ 221 812,50

Address

Sparhoekdreef 57
9880 Aalter

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)